KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Emergent BioSolutions (EBS) Cash from Operations (2016 - 2026)

Emergent BioSolutions has reported Cash from Operations over the past 17 years, most recently at 33800000.0 for Q1 2026.

For Q1 2026, Cash from Operations fell 201.79% year-over-year to 33800000.0; the TTM value through Mar 2026 reached 148000000.0, up 34.42%, while the annual FY2025 figure was 170600000.0, 190.63% up from the prior year.
Cash from Operations for Q1 2026 was 33800000.0 at Emergent BioSolutions, down from 77700000.0 in the prior quarter.
Over five years, Cash from Operations peaked at 153700000.0 in Q3 2024 and troughed at 184000000.0 in Q1 2023.
A 5-year average of 2641176.47 and a median of 11200000.0 in 2025 define the central range for Cash from Operations.
Biggest five-year swings in Cash from Operations: plummeted 831.37% in 2022 and later soared 197.25% in 2025.
Year by year, Cash from Operations stood at 92800000.0 in 2022, then tumbled by 65.41% to 32100000.0 in 2023, then plummeted by 348.91% to 79900000.0 in 2024, then soared by 197.25% to 77700000.0 in 2025, then crashed by 143.5% to 33800000.0 in 2026.
Business Quant data shows Cash from Operations for EBS at 33800000.0 in Q1 2026, 77700000.0 in Q4 2025, and 2300000.0 in Q3 2025.